Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

The Windsor Framework marks a significant change in the UK's post-Brexit regulatory space, particularly for the ...

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

As such, the 2nd Peptide Formulation & Delivery Innovation Summit (June 24 - 26, 2025 | Boston, MA) returns as the only ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

The 6th TCR-based Therapies Summit returns as the only forum created solely for TCR experts pioneering best-in-class cell- ...

Novel analytical methodologies, real-world data (RWD), innovative trial designs, and new technologies are crucial to optimise ...

Other companies use customer reference and patient data to improve operational agility as they launch and scale their first ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...

"Many loss of pulse incidents happen when the person is alone, leaving them with effectively no chance of receiving ...

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...